ImmunityBio (26CA) Price & Analysis

17 Followers

26CA Stock Chart & Stats

€6.75

-€0.17(-2.76%)

At close: Jul 28 4:00 PM EDT

€6.75

-€0.17(-2.76%)

Day’s Range― - ―

52-Week Range€1.68 - €10.40

Previous CloseN/A

Volume4.00K

Average Volume (3M)1.25K

Market Cap

€7.87B

Enterprise Value€10.07K

Total Cash (Recent Filing)€357.37M

Total Debt (Recent Filing)€813.06M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Nov 05, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding1,059,836,300

10 Day Avg. Volume2,095

30 Day Avg. Volume1,252

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)-3.65

Price to Sales (P/S)16.08

P/FCF Ratio-5.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€11.36

Price Target Upside68.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.73

Revenue Forecast (FY)€197.21M

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Gross MarginsRapid revenue expansion shows growing commercialization of ImmunityBio’s offerings, while the exceptionally high gross margin indicates substantial value capture on sales. If maintained, this combination can provide a stronger base for reinvestment and eventual operating leverage as the business scales.

Expanding International Regulatory ApprovalsAuthorization in additional countries broadens ANKTIVA’s addressable commercial market and creates more opportunities for physician adoption, reimbursement, and partnership activity. The UAE decision also extends the product into multiple cancer settings, strengthening its longer-term commercialization platform.

Substantial Debt ReductionThe sharp reduction in debt lowers the company’s direct repayment burden and may reduce interest-related pressure on future cash flows. Although negative equity remains a major weakness, a smaller debt balance gives management more flexibility than the prior capital structure provided.

Bears Say

Severe And Persistent LossesThe scale of losses remains disproportionate to current revenue, showing that ImmunityBio has not yet aligned its cost structure with its commercial base. Continued large operating deficits could delay breakeven, consume capital, and limit the company’s ability to fund expansion internally.

Negative Equity And Weak Capital PositionA deeply negative equity position signals accumulated deficits and leaves the balance sheet with limited financial resilience. This can constrain strategic flexibility and increase reliance on financing or other capital-raising measures to support operations and commercialization over the coming quarters.

Persistent Negative Cash FlowThe company is still not self-funding despite its revenue growth and must finance ongoing operations while cash generation remains negative. Deteriorating free cash flow increases the importance of external capital and could restrict investment in trials, launches, and broader commercial execution.

ImmunityBio News

What 235,000 Stock Periods Suggest About Revenue Growth and Returns: Inside the Golden Eagle Dynamic Hypergrowth ETF (HYP)

Most equity screens sort companies on some version of price: price-to-earnings, price-to-book, forward multiples. Golden Eagle Strategies built...

6d ago

ImmunityBio call volume above normal and directionally bullish

Bullish option flow detected in ImmunityBio (IBRX) with 37,789 calls trading, 3x expected, and implied vol increasing almost...

8d ago

IBRX

ImmunityBio put volume heavy and directionally bearish

Bearish flow noted in ImmunityBio (IBRX) with 14,599 puts trading, or 7x expected. Most active are Jan-27 9...

21d ago

IBRX

ImmunityBio’s New Sepsis Trial: Early-Stage Data With High-Stakes Market Potential

Immunitybio Inc ($IBRX) announced an update on their ongoing clinical study. ImmunityBio, Inc. (IBRX) is launching a Phase...

5d ago

IBRX

ImmunityBio’s New Bladder Cancer Combo Trial: What Investors Should Know

Immunitybio Inc ($IBRX) announced an update on their ongoing clinical study. The phase 1b study “Open-Label, Single-Arm, Phase...

6d ago

IBRX

ImmunityBio (IBRX) Faces Investor Scrutiny as Defendants Move to Dismiss Securities Lawsuit Over Podcast Statements

Defendants in the securities case against ImmunityBio, Inc. ($IBRX) and its Executive Chairman Patrick Soon-Shiong have asked a...

6d ago

IBRX

Unusually active option classes on open August 10th

Unusual total active option classes on open include: Cooper Companies (COO), Aris Water Solutions, Inc. (ARIS), Xylem (XYL),...

2M ago

COO

ImmunityBio appoints Kim as Vice Chairman

ImmunityBio (IBRX) announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will...

2M ago

IBRX

BTIG’s Mukherjee Reiterates Buy on ImmunityBio as ANKTIVA Growth, Upcoming QUILT-2.005 Milestones Support Unchanged $12 Price Target

BTIG analyst Jeet Mukherjee has maintained their bullish stance on IBRX stock, giving a Buy rating yesterday. Jeet...

2M ago

IBRX

ImmunityBio: ANKTIVA’s Sustained Growth and Regulatory Catalysts Support Reaffirmed Buy Rating and Unchanged $15 Price Target

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on ImmunityBio, with...

2M ago

IBRX

ImmunityBio reports Q2 EPS (22c) vs. (10c) last year

Reports Q2 revenue $51.2M, consensus $49.7M. “Our record quarterly net product revenue of $50.7 million and eighth consecutive...

2M ago

IBRX

ImmunityBio wins UAE approval for ANKTIVA cancer therapies

ImmunityBio ( ($IBRX) ) has shared an announcement. On July 29, 2026, ImmunityBio announced that the Emirates Drug...

2M ago

IBRX

Unusually active option classes on open June 29th

Unusual total active option classes on open include: Arxis, Inc. (ARXS), Comcast (CMCSA), MAGS ETF (MAGS), Charter (CHTR),...

3M ago

WEN

Most of the Fastest Growing Companies Are Not in the S&P 500: How the Golden Eagle Dynamic Hypergrowth ETF is Built to Capture Them

As of June 8, 2026, the so-called Magnificent Seven accounted for roughly 33.8% of the S&P 500, and...

3M ago

26CA FAQ

What was ImmunityBio’s price range in the past 12 months?

ImmunityBio lowest stock price was €1.68 and its highest was €10.40 in the past 12 months.

What is ImmunityBio’s market cap?

ImmunityBio’s market cap is €7.87B.

When is ImmunityBio’s upcoming earnings report date?

ImmunityBio’s upcoming earnings report date is Nov 05, 2026 which is in 36 days.

How were ImmunityBio’s earnings last quarter?

ImmunityBio released its earnings results on Aug 04, 2026. The company reported -€0.194 earnings per share for the quarter, missing the consensus estimate of -€0.071 by -€0.124.

Is ImmunityBio overvalued?

According to Wall Street analysts ImmunityBio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ImmunityBio pay dividends?

ImmunityBio does not currently pay dividends.

What is ImmunityBio’s EPS estimate?

ImmunityBio’s EPS estimate is -0.06.

How many shares outstanding does ImmunityBio have?

ImmunityBio has 1,059,836,300 shares outstanding.

What happened to ImmunityBio’s price movement after its last earnings report?

ImmunityBio reported an EPS of -€0.194 in its last earnings report, missing expectations of -€0.071. Following the earnings report the stock price went down -5.742%.

Which hedge fund is a major shareholder of ImmunityBio?

Currently, no hedge funds are holding shares in DE:26CA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ImmunityBio Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

56.31%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

ImmunityBio

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

ImmunityBio (26CA) Earnings & Revenues

Historic Earnings Reports

26CA Stock 12 Month Forecast

Average Price Target

€11.36

▲(68.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","14":"€14","3.5":"€3.5","10.5":"€10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.11314895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.364729089999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€11.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.49051916,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,7.304088380769231,7.788176761538462,8.272265142307692,8.756353523076923,9.240441903846154,9.724530284615385,10.208618665384616,10.692707046153846,11.176795426923077,11.660883807692308,12.144972188461537,12.62906056923077,{"y":13.11314895,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,7.169594545384616,7.519189090769231,7.868783636153847,8.218378181538462,8.567972726923077,8.917567272307693,9.267161817692308,9.616756363076924,9.96635090846154,10.315945453846155,10.665539999230768,11.015134544615384,{"y":11.364729089999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,7.102347627692308,7.3846952553846155,7.667042883076923,7.949390510769231,8.23173813846154,8.514085766153846,8.796433393846154,9.078781021538461,9.36112864923077,9.643476276923076,9.925823904615385,10.208171532307691,{"y":10.49051916,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.973,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.086,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.061,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.704,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.174,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.92,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >